Tango Therapeutics

Update in progress

TNGX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tango Therapeutics is a precision oncology company focused on discovering and developing drugs for defined patient populations with unmet needs. It is advancing methylthioadenosine (MTAP)-cooperative PRMT5 inhibitors, including TNG462 in a Phase 1/2 trial for pancreatic and lung cancer, and TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma. It is also developing TNG260, a REST co-repressor to counter STK11 loss-driven immune evasion in lung cancer. Founded in 2017 and based in Boston.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive